These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27395338)

  • 1. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
    Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
    J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
    Petrunak EM; Rogers SA; Aubé J; Scott EE
    Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
    Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
    Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
    Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
    Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orteronel for the treatment of prostate cancer.
    Van Hook K; Huang T; Alumkal JJ
    Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
    DeVore NM; Scott EE
    Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
    Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
    Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
    Salem M; Garcia JA
    Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
    Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
    J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
    Toren PJ; Kim S; Pham S; Mangalji A; Adomat H; Guns ES; Zoubeidi A; Moore W; Gleave ME
    Mol Cancer Ther; 2015 Jan; 14(1):59-69. PubMed ID: 25351916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
    Yin L; Hu Q
    Nat Rev Urol; 2014 Jan; 11(1):32-42. PubMed ID: 24276076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
    Alyamani M; Li Z; Berk M; Li J; Tang J; Upadhyay S; Auchus RJ; Sharifi N
    Cell Chem Biol; 2017 Jul; 24(7):825-832.e6. PubMed ID: 28648378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
    Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
    Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.